Botox in Korea is not "Botox" the brand. It is one of more than half a dozen Korean botulinum toxin products competing on price, onset speed, diffusion profile, and increasingly on global regulatory approvals. Patients walk into a Gangnam clinic, see a price for "botox," and rarely ask which one. They should.
The Korean toxin landscape in 2026
Major Korean-made botulinum type A products on Gangnam menus:
- Botulax / Letybo (Hugel) — the largest Korean brand by market share. Botulax in Korea, marketed as Letybo in the US (FDA-approved February 2024), EU, and China.
- Meditoxin / Neuronox (Medytox) — long-established Korean brand with a substantial global footprint.
- Innotox (Medytox) — a liquid formulation of botulinum toxin, marketed as more convenient and faster-acting in some clinic protocols.
- Nabota / Jeuveau (Daewoong) — FDA-approved as Jeuveau in the US for glabellar lines.
- Liztox (Huons) — newer Korean entrant, popular with cost-sensitive clinics.
- Hutox (Huons) — sister product, frequently bundled in package pricing.
- ReNTox (Pharma Research) — newer-generation entrant gaining adoption.
How clinicians actually choose
Korean dermatologists and plastic surgeons select based on a combination of factors:
- Patient-reported onset speed. Some products are perceived as faster-acting; this can matter for events or pre-trip timing.
- Diffusion profile. Wider-diffusing products are useful for skin botox / microbotox; narrower-diffusing products are preferred for masseter and brow.
- Track record with that specific patient. Patients who develop antibody resistance to one product may switch brands.
- Price. Newer Korean brands often price below the established leaders.
- Global recognition. Patients who plan touch-ups in their home country sometimes prefer the brand sold internationally (Letybo, Jeuveau).
What about brand differences in clinical effect?
Head-to-head Korean dermatology research has shown all licensed Korean botulinum toxin type A products are clinically effective for cosmetic indications. Differences in onset time, longevity, and diffusion are typically modest in well-conducted comparisons. Marketing language often overstates differences.
Practical implication: if your clinic is reputable and the product is MFDS-permitted, the choice between Korean brands is rarely a deal-breaker for a typical glabellar/forehead/crow\'s-feet treatment. It matters more for masseter (where diffusion control affects smile aesthetics) and skin-botox (where diffusion is the point).
Asking your clinic the right questions
- Which Korean brand are you using and why?
- Is it MFDS-permitted and stored properly (refrigerated, in date)?
- What is the dosing — in units, not "vials"?
- If I have had Korean botox before, can you match the previous brand or note any allergic/resistance history?
Counterfeit and grey-market risk
Counterfeit botulinum toxin is a global problem. In Korea, the risk is concentrated at very low-priced packages and unlicensed providers. Two safeguards:
- Choose a licensed clinic with a posted medical license — Korean clinics legally must display this.
- If the price is dramatically below market — say half of nearby clinics for the same units — ask explicitly about product source. Real product is not free.
2026 price ranges in Gangnam (USD)
- Forehead/glabellar/crow\'s-feet (typical 25–50 units): $80–$200 per area.
- Masseter (jaw slimming, 25–40 units per side): $200–$500.
- Skin botox / microbotox full-face package: $200–$500 per session.
- Premium clinics in Cheongdam or Apgujeong using imported brands: 30–60% above the budget tier.
Brand choice is a smaller decision than people think. Surgeon experience, dosing accuracy, and follow-up policy are larger ones. Ask all three, and the brand becomes a footnote.